Abstract
A 48-year-old male patient was admitted with acquired immunodeficiency syndrome (stage III, Centers for Disease Control 1993) and viremic hepatitis B. Blood CD4 count was 15/μl. Discontinuation of prednisolone, previously prescribed by the patient's family practitioner because of elevated liver enzymes, resulted in severe hepatitis (alanine aminotransferase > 300U/1). Administration of interferon-α, (9 × 106U s.c. 3 × weekly) was initiated. Serum markers of viral replication disappeared, and aminotransferase levels returned to normal within a few weeks. The patient's serum was found negative for HBsAg after 3 months. Immunohistochemical analysis of liver biopsies before and during interferon therapy showed disappearance of all hepatitis B virus antigens and a marked reduction in inflammatory activity. Hepatitis B virus seroconversion remained stable until the patient died from the syndrome 2 years later. This case shows that in spite of severe HIV-associated immune deficiency with CD4 counts constantly below 100/μl, interferon-α can lead to sustained serological and histological improvement of viremic hepatitis B. Previous administration and discontinuation of cortisone may have helped to reach this effect.
Abbreviations
- HBV:
-
hepatitis B virus
- HIV:
-
human immunodeficiency virus
- IFN:
-
interferon
References
Bain VG, Daniels HM, Chanas A, Alexander GJM, Williams R (1989) Foscarnet therapy in chronic hepatitis B virus E antigen carriers. J Med Virol 29: 152–155
Bodsworth NJ, Cooper DA, Donovan B (1991) The influence of human immunodeficiency virus type I on the development of the hepatitis B virus carrier state. J Infect Dis 163:1138–1140
Buller RM, Holmes KL, Hügin A, Frederickson TN, Morse III HC (1987) Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells. Nature 328: 77–79
Buti M, Esteban R, Esteban JI, Gonzalez A, Guardia J (1987) Severe hepatic failure after ARA-A-prednisolone for chronic type B hepatitis (letter). Gastroenterology 92: 274–275
Davis GL (1989) Interferon treatment of viral hepatitis in immunocompromised patients. Semin Liver Dis 9: 267–272
Degos F, Lugassy C, Degott C, Debure A, Carnot F, Theirs V, Tiollais P, Kreis H, Brechot C (1988) Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. Gastroenterology 94: 151–156
Gilson RJ, Hawkins AE, Kelly GK, Gill SK, Weller IV (1991) No effect of zidovudine on hepatitis B virus in homosexual men with symptomatic HIV-1 infection. AIDS 5: 217–220
Gordon SC, Reddy KR, Gould EE, McFadden R, O'Brien C, De Medina M, Jeffers LJ, Schiff ER (1986) The spectrum of liver disease in the acquired immunodeficiency syndrome. J Hepatol 2: 475–484
Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, Schable CA, Coleman PJ, Ostrow DN, Francis DP (1991) Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 163: 454–459
Hess G, Manus M, Hütteroth T, Meyer zum Büschenfelde K-H (1987) Discontinuation of immunosuppressive therapy in hepatitis B surface antigen-positive chronic hepatitis: effect on viral replication and liver cell damage. Digestion 36: 47–54
Hess G, Rossol S, Voth R, Gerken G, Ramadori G, Drees N, Meyer zum Büschenfelde K-H (1989) Treatment of patients with chronic type hepatitis B and concurrent human immunodeficiency virus infection with a combination of interferon alpha and azidothymidine: a pilot study. Digestion 43: 56–59
Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96: 447–449
Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, Waggoner JG, Jones EA, Seeff LB (1986) A short course of prednisolone in chronic type B hepatitis: report of a randomized, double-blind, placebo-controlled trial. Ann Intern Med 104: 12–17
Housset C, Pol S, Carnot F, Dubois F, Nalpas B, Housset B, Berthelot P, Brechot C (1991) Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 15: 578–583
Katkov WN, Dienstag JL (1991) Prevention and therapy of viral hepatitis. Semin Liver Dis 11: 165–174
Kingsley LA, Rinaldo CR, Lyter DW, Valdiserri RO, Belle SH, Ho M (1990) Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. JAMA 264: 230–234
Koblin BA, Tylor PE, Rubinstein P, Stevens CE (1992) Effect of duration of hepatitis B virus infection on the association between human immunodeficiency virus type-1 and hepatitis B viral replication. Hepatology 15: 590–592
Krogsgaard K (1994) Does corticosteroid pretreatment enhance the effect of alfa interferon treatment in chronic hepatitis B? J Hepatol 20: 159–162
Lau JYN, Wright T (1993) Molecular virology and pathogenesis of hepatitis B. Lancet 342:1335–1340
Levy P, Marcellin P, Martinot-Peignoux M, Degott C, Nataf J, Benhamou JP (1990) Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology 12: 570–574
Liaw Y-F, Lin S-M, Chen T-J, Chien R-N, Sheen IS, Chu C-M, Chu C-M (1994) Beneficial effect of prednisolone withdrawal by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. J Hepatol 20: 175–180
McNair ANB, Main J, Thomas HC (1992) Interactions of the human immunodeficiency virus and the hepatotropic viruses. Semin Liver Dis 12: 188–196
Mills TC, Lee E, Perillo R (1990) Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. Gastroenterology 99: 519–524
Nair PV, Tong MJ, Stevenson D, Roskamp D, Boone C (1986) A pilot study on the effects of prednisone withdrawal on serum hepatitis B virus DNA and HBeAg in chronic active hepatitis B. Hepatology 6: 1319–1324
Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht H-J, Vitiello A., Chesnut R, Person JL, Redeker AG, Chisari FV (1993) HLA-A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150: 4659–4671
Novick DM, Farci P, Croxson TS, Taylor MB, Schneebaum VW, Lai ME, Bach N, Senie RT, Gelb, AM, Kreek MJ (1988) Hepatitis D virus and human immunodeficiency virus antibodies in parenteral drug abusers who are hepatitis B surface antigen positive. J Infect Dis 158: 795–803
Perrillo RP (1993) Antiviral therapy of chronic hepatitis B: past, present, and future. J Hepatol 17 [Suppl 3]: 56–63
Perillo RP, Regenstein FG, Roodman ST (1986) Chronic hepatitis B in asymptomatic homosexual men with antibody to human immunodeficiency virus. Ann Int Med 105: 382–383
Perillo RP, Regenstein FG, Peters MG, DeSchryver-Kecskemeti K, Bodicky CJ, Campbell CR, Kuhns MC (1988) Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. Ann Intern Med 109: 95–100
Perillo RP, Schiff ER, Davis GL, Bodenheimer HC, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM, Sampliner R, Feit D, Lefkowitch J, Kuhns M, Meschievitz C, Sanghvi B, Albrecht J, Gibas A, the Hepatitis Interventional Therapy Group (1990) A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 321: 295–301
Peters M (1989) Mechanisms of action of interferons. Semin Liver Dis 9:235–239
Rieber EP, Rank G (1994) CDw60: a marker for human CD8+ helper cells. J Exp Med 179: 1385–1390
Scharschmidt BF, Held MJ, Hollander HH, Read AE, Lavine JE, Veereman G, McGuire RF, Thaler MM (1992) Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 117: 837–838
Solomon RE, Van Raden M, Kaslow RA, Lyter D, Visscher B, Farzadegan H, Phair J (1990) Association of hepatitis surface and core antibody with acquisition and manifestations of human immunodeficiency virus type I infection. Am J Publ Health 80: 1475–1478
Vento S, Di Perri G, Luzzati R, Cruciani M, Garofano T, Mengoli C, Concia E, Bassetti D (1989) Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet I: 332–333
Visco G, Alba L, Grisetti S, Guarascio P, Narciso P, Sette P, Struglia C, Tossini G, Tozzi V (1993) Zidovudine plus interferon alpha-2b treatment in patients with HIV and chronic active viral hepatitis. Gut 34 [Suppl 2]: 107–1088
Waite J, Gilson RJC, Weller IV, Lacey CJ, Hambling MH, Hawkins A, Briggs M, Tedder RS (1988) Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS 2: 443–448
Author information
Authors and Affiliations
Additional information
Correspondence to: G. Gerken
Rights and permissions
About this article
Cite this article
Wölfe, T., Schirmacher, P., Schlaak, J. et al. Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and advanced human immunodeficiency virus infection. Clin Investig 72, 1030–1036 (1994). https://doi.org/10.1007/BF00577750
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00577750